trial

A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients

NCTId NCT04521868
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 125 (actual)
Sponsored by Central South University
Primary completion 2022-08-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
125 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2020-08-31
Primary completion
2022-08-12
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Sulforaphane

Sponsors

Central South UniversityLead Sponsor

Investigators

1
Renrong Wu, M.D., Ph.D.Principal Investigator

Sites

1 total
Changsha, China

Linked catalysts

1
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients — primary completion2022-08-12

Facts & assertions

4 sourced
Enrollment
125
Phase
PHASE2
Primary Completion Date
2022-08-12
Status
COMPLETED
relationships
The graph out of here
drug
Sulforaphane
drug
lead_sponsor
Central South University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Renrong Wu, M.D., Ph.D.
person